

2 ASTRAZENECA AND OUR YEAR IN BRIEF

ASTRAZENECA IS ONE OF THE WORLD'S LEADING PHARMACEUTICAL COMPANIES WITH A BROAD RANGE OF MEDICINES DESIGNED TO FIGHT DISEASE IN IMPORTANT AREAS OF HEALTHCARE. BACKED BY STRONG SCIENCE AND WIDE-RANGING COMMERCIAL SKILLS,

WE ARE COMMITTED TO THE SUSTAINABLE DEVELOPMENT OF OUR BUSINESS AND THE DELIVERY OF A FLOW OF NEW MEDICINES THAT BRING BENEFIT FOR PATIENTS AND CREATE ENDURING VALUE FOR OUR SHAREHOLDERS AND SOCIETY.

FINANCIAL HIGHLIGHTS

SALES \$M

		GROWTH
08	31,601	+3%
07	29,559	+7%
06	26,475	+11%

OPERATING PROFIT \$M

		GROWTH
Core 08	10,958	+9%
Reported 08	9,144	+4%
Reported 07	8,094	-4%
Reported 06	8,216	+28%

CORE EARNINGS PER ORDINARY SHARE \$

		GROWTH
08	5.10	+8%
07	4.38	+10%
06	3.92	+33%

DISTRIBUTIONS TO SHAREHOLDERS: DIVIDENDS AND SHARE RE-PURCHASES \$M

● DIVIDENDS ○ SHARE RE-PURCHASES

08	2,739	610
07	2,641	4,170
06	2,220	4,147

DIVIDEND FOR 2008

	\$	Pence	SEK	Payment date
First interim dividend	0.55	27.8	3.34	15 September 2008
Second interim dividend	1.50	104.8	12.02	16 March 2009
Total	2.05	132.6	15.36	

PRODUCT PERFORMANCE SUMMARY \$M

NEXIUM -2%

08	5,200
07	5,216
06	5,182

SEROQUEL +9%

08	4,452
07	4,027
06	3,416

CRESTOR +26%

08	3,597
07	2,796
06	2,028

PULMICORT +0%

08	1,495
07	1,454
06	1,292

ATACAND +10%

08	1,471
07	1,287
06	1,110

CASODEX -12%

08	1,258
07	1,335
06	1,206

LOSEC/PRILOSEC -14%

08	1,055
07	1,143
06	1,371

MERREM +13%

08	897
07	773
06	604

SELOKEN/TOPROL-XL -46%

08	807
07	1,438
06	1,795

**REPORTED BASIC EARNINGS
PER ORDINARY SHARE \$**

		GROWTH
08	4.20	+2%
07	3.74	-5%
06	3.86	+34%

**NET CASH FLOW
FROM OPERATING ACTIVITIES \$M**

08	8,742
07	7,510
06	7,693

SYMBICORT +22%

08	2,004
07	1,575
06	1,184

ARIMIDEX +4%

08	1,857
07	1,730
06	1,508

SYNAGIS¹ n/m

08	1,230
07	618

ZOLADEX -3%

08	1,138
07	1,104
06	1,008

FLUMIST¹ n/m

08	104
07	53

2008 IN BRIEF

- > Sales up 3% to \$31,601 million.
- > *Crestor* sales up 26% to \$3,597 million; *Symbicort* up 22% to \$2,004 million; *Seroquel* up 9% to \$4,452 million; and *Arimidex* up 4% to \$1,857 million. *Nexium* sales down 2% to \$5,200 million.
- > Our product portfolio now includes 11 medicines with annual sales of more than \$1 billion each.
- > Sales in Emerging Markets reached \$4,273 million for the full year, up 16%.
- > Investment in R&D in line with 2007 at \$5.2 billion.
- > Core operating profit up 9% to \$10,958 million.
- > Core operating margin improved to 34.7% of sales on operational efficiencies in all functional areas.
- > Core EPS for the full year increased by 8% to \$5.10.
- > Reported EPS for the full year increased by 2%, reflecting higher intangible asset impairments and a full year of MedImmune amortisation compared with 2007.
- > Dividend up 10% to \$2.05 for the full year.
- > Cash distributions to shareholders totalled \$3,349 million (dividends \$2,739 million; share re-purchases \$610 million).
- > Net debt reduced by \$1.9 billion on strong cash performance and investment discipline.
- > Eight significant regulatory life-cycle management submissions; two product submissions. Phase III pipeline volume remains constant. Phase II pipeline increased by over 50%. Nominated 32 FGLPs and exceeded our target for progressing these into man.
- > New initiatives extend the scope of restructuring programme to sustain long-term competitiveness.
- > 35 significant business development transactions including extensions of existing agreements.
- > Summary Judgment Motion granted to AstraZeneca in the patent infringement actions commenced against two generic drug manufacturers in the US following abbreviated new drug applications relating to *Seroquel*.
- > Settlement of US *Nexium* patent litigation with enforceability of disputed *Nexium* patents conceded. Other patent litigation continuing in the US against generic manufacturers following abbreviated new drug applications relating to *Nexium*.
- > New Code of Conduct launched in over 40 languages and all employees trained.

Growth rates expressed above are CER growth rates.

¹ Acquired in June 2007.